| 11 |
[2024] CELLeBRAIN CEO Haeyoung Seo presents at Korea-China Bio Innovation Forum in Hangzhou… Engages in global partnering
admin
|
2024.05.25
|
Votes 0
|
Views 152
|
admin |
2024.05.25 |
2024 |
0 |
152 |
| 12 |
[2024] CELLeBRAIN presented at Korean Society for Clinical Pharmacology and Therapeutics – 2024 Annual Meeting
admin
|
2024.04.26
|
Votes 0
|
Views 1041
|
admin |
2024.04.26 |
2024 |
0 |
1041 |
| 13 |
[2024] CELLeBRAIN CEO pitches directly at Gyeongbuk R&D Special Zone BIO+ IR DAY 2024
admin
|
2024.03.04
|
Votes 0
|
Views 123
|
admin |
2024.03.04 |
2024 |
0 |
123 |
| 14 |
[2023] CELLeBRAIN highlighted as one of Hanmi Pharmaceutical’s promising unlisted portfolio companies
admin
|
2023.12.12
|
Votes 0
|
Views 124
|
admin |
2023.12.12 |
2023 |
0 |
124 |
| 15 |
[2023] CELLeBRAIN promotes global partnering and technologies with Japanese companies at BioJapan 2023
admin
|
2023.10.11
|
Votes 0
|
Views 647
|
admin |
2023.10.11 |
2023 |
0 |
647 |
| 16 |
[2023] CELLeBRAIN showcases anticancer technologies and promotes global partnering at the 2023 Global Biotech Showcase
admin
|
2023.07.12
|
Votes 0
|
Views 102
|
admin |
2023.07.12 |
2023 |
0 |
102 |
| 17 |
[2022] CELLeBRAIN selected for a 1.2 billion KRW national new drug development project by KDDF at candidate material stage
admin
|
2022.09.13
|
Votes 0
|
Views 190
|
admin |
2022.09.13 |
2022 |
0 |
190 |
| 18 |
[2022] CELLeBRAIN selected as one of 20 innovative biotech companies supported by Korea Institute of Toxicology
admin
|
2022.07.27
|
Votes 0
|
Views 118
|
admin |
2022.07.27 |
2022 |
0 |
118 |
| 19 |
[2022] CELLeBRAIN selected for early-stage investment portfolio by Timeworks Investment
admin
|
2022.06.17
|
Votes 0
|
Views 112
|
admin |
2022.06.17 |
2022 |
0 |
112 |
| 20 |
[2021] CELLeBRAIN joins Korean Alliance for Stem Cells and Regenerative Medicine (KASCRM) as a member company
admin
|
2021.08.18
|
Votes 0
|
Views 118
|
admin |
2021.08.18 |
2021 |
0 |
118 |
